Breast Disease · 2024 · 17 citations · 24 references
MedicineImmunologyOncologyApoptosisCancer ImmunologyImmunotherapyApoptosis In CancerCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmunotherapy For Breast CancerPd-1 SignalingPd-l1 BlockadeProgrammed Cell Death Ligand 1 InhibitionProgrammed Cell Death Ligand 1 SignalingProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 Signaling
INTRODUCTION: Immunotherapy has shown encouraging outcomes in breast cancer (BC) treatment in recent years. The programmed cell death ligand 1 (PD-L1) transmembrane protein is suggested to function as a co-inhibitory factor in the immune response, where it collaborates with programmed cell death protein 1 (PD-1) to stimulate apoptosis, suppress cytokine release from PD-1 positive cells, and limit the growth of PD-1 positive cells. Furthermore, in many malignancies, PD-L1 reduces the immune system's response to neoplastic cells. These observations suggest that the PD-1/PD-L1 axis plays a vital role in cancer therapy and the regulation of cancer immune escape mechanisms. This review aimed to provide an overview of the functions of PD-1 and PD-L1 in BC cancer therapy. METHODS: This research design is a literature review. The style is a traditional review on topics or variables relating to the PD-1/PD-L1 pathway. A literature search was carried out using three online databases. RESULTS: The search using the keywords yielded a total of 248 studies. Each result was filtered again according to the inclusion and exclusion criteria, resulting in a final total of 4 studies to be included in the literature review. CONCLUSIONS: The combination of PD-1/PD-L1 is essential for many malignancies. According to the evidence presented, this combination presents both an opportunity and a challenge in cancer treatment. Since many solid cancers, especially BC, express high levels of PD-1/PD-L1, cancer treatment mainly involves targeted therapies.
24
Hallmarks of Cancer: New Dimensions
Cancer Discovery · 2022 · 9.1K citations · Full text
Medicine, Cancer Biology, Oncology +17
Alan S. Coates, Eric P. Winer, Aron Goldhirsch et al. · Annals of Oncology · 2015 · 1.8K citations · Full text
PD-1/PD-L1 pathway: current researches in cancer.
Yanyan Han, Dandan Liu, Lianhong Li · PubMed · 2020 · 1.6K citations · Full text
Life Sciences, Immunology, Oncology +17
Mary L. Disis · Journal of Clinical Oncology · 2010 · 485 citations
Medicine, Immunology, Oncology +17